NCT05052372 - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2021

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions

Bladder CancerUrothelial CarcinomaTransitional Cell CarcinomaPlatinum-Resistant Urothelial CarcinomaBladder Urothelial CarcinomaFGFR MutationFGFR2 Gene MutationFGFR3 Gene MutationFGFR2 AmplificationLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaRefractory Bladder CarcinomaRefractory Bladder Urothelial Carcinoma

Interventions

DRUG

Balversa

BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery

Trial Locations (1)

27612

xCures Virtual Site, Raleigh